Results 141 to 150 of about 17,555 (296)

Improving assessment of demand for postpartum tubal ligation among publicly insured women in Texas. [PDF]

open access: yesContraception, 2021
Potter JE   +5 more
europepmc   +1 more source

Depletion of the RNA‐Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells

open access: yesAdvanced Science, EarlyView.
ADAR1 is upregulated in NK cells from melanoma patients, impairing their function. Its loss enhances NK cell tumor infiltration and cytotoxicity in vitro and in vivo. Mechanistically, ADAR1 deficiency destabilizes CD38 mRNA to reduce its expression, thereby increasing NK cell mobility and killing, which nominates it as a therapeutic target for NK cell ...
Shuhan Chen   +11 more
wiley   +1 more source

Association of oral contraceptives and tubal ligation with risk of early natural menopause. [PDF]

open access: yesHum Reprod, 2021
Langton CR   +7 more
europepmc   +1 more source

EIF5A Couples Translational Control With Transcriptional Reprogramming Through Chromocenter Reorganization During Spermiogenesis

open access: yesAdvanced Science, EarlyView.
The translation factor Eukaryotic translation initiation factor 5A (eIF5A) is essential for male fertility in mice. It supports the translation of proteins crucial for heterochromatin organization and acrosome formation. eIF5A deficiency disrupts chromocenter integrity, increases chromatin accessibility, and causes transcriptional dysregulation ...
Yuling Cai   +15 more
wiley   +1 more source

Nanoparticle Immunoadjuvant Complexes Augment Germinal Center Responses to Vaccination

open access: yesAdvanced Science, EarlyView.
Scaffolding IL‐21 on the surface of a self‐assembling nanoparticle immunogen drives improved germinal center and humoral immune responses. These nanoparticle immunoadjuvant complexes (NICs) functionally modulate the germinal center driving improved somatic hypermutation and antibody maturation, suggesting this platform has potential utility as a ...
Nicholas J. Tursi   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy